Premium
Immunohistochemical Study of Oncogenic and Prognostic Markers in Sebaceous Tumors
Author(s) -
Cassarino David S.,
Auerbach Aaron,
Barrett Terry
Publication year - 2005
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/j.0303-6987.2005.320ai.x
Subject(s) - immunohistochemistry , sebaceous carcinoma , pathology , staining , atypical hyperplasia , adenoma , sebaceous gland , hyperplasia , cyclin d1 , carcinoma , medicine , biology , cancer , cell cycle
Background: Sebaceous tumors are adnexal tumors with usually low‐gradebehavior. The distinction between sebaceous adenomas and carcinomas, especially on small biopsies from sensitive sites (i.e., ocular), may bedifficult. We compared the expression of various oncogenic andprognostic markers by immunohistochemistry in order to distinguishbenign from malignant sebaceous tumors.Design: 10 sebaceous adenomas, 10 sebaceous carcinomas, and 5 cases ofsebaceous hyperplasia, were studied with antibodies directed againstKi‐67 (mib‐1), bcl‐2, p53, p21, p27, c‐erb2 (Her‐2/neu), CD117 (c‐kit), cyclin D1, MDM2, and CD99 (mic2).Results: We found that sebaceous carcinomas differed from sebaceousadenomas by having increased staining for p53 (50% vs 11%) and mib‐1(average 1.8+ vs. 1.0+), and significantly reduced levels of bcl‐2 (7%vs 62%) and p21 (16% vs 34%).The other markers did not differ significantly, although there was atrend towards more Her‐2/neu staining in the carcinomas. No cases showedany c‐kit staining.Conclusions: We have shown that several markers, including mib‐1, p53, p21, and bcl‐2, are expressed at significantly different levels insebaceous carcinomas versus adenomas, and may be of use indiagnostically challenging cases. Whether or not any of these markerswill prove useful in predicting prognosis remains controversial.